Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

por Lee, Chung-Han, Motzer, Robert
Publicado 2018

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

por Molina, Ana M., Ginsberg, Michelle S., Motzer, Robert J.
Publicado 2010

A brief symptom index for advanced renal cell carcinoma

por Eton, David T, Cella, David, Bacik, Jennifer, Motzer, Robert J
Publicado 2006

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

por Khosravan, Reza, Motzer, Robert J., Fumagalli, Elena, Rini, Brian I.
Publicado 2016

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer

por Russo, Paul, Synder, Mark, Vickers, Andrew, Kondagunta, Varuni, Motzer, Robert
Publicado 2007

Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example

por Burotto, Mauricio, Wilkerson, Julia, Stein, Wilfred, Motzer, Robert, Bates, Susan, Fojo, Tito
Publicado 2014

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

por Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.
Publicado 2018

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

por Lee, Chung-Han, Wan, Yin, Smith, Alan, Xie, Ran, Motzer, Robert J.
Publicado 2021

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

por Yang, Lin, Alyasova, Anna, Ye, Dingwei, Ridolfi, Antonia, Dezzani, Luca, Motzer, Robert J.
Publicado 2018

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)

por Shah, Ruchitbhai, Botteman, Marc, Solem, Caitlyn T., Luo, Linlin, Doan, Justin, Cella, David, Motzer, Robert J.
Publicado 2019

Neutrophil Chemokines Secreted by Tumor Cells Mount a Lung Antimetastatic Response during Renal Cell Carcinoma Progression

por López-Lago, Miguel A., Posner, Shai, Thodima, Venkata J., Molina, Ana M., Motzer, Robert J., Chaganti, RSK
Publicado 2012

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial

por Cella, David, Jensen, Sally E, Hahn, Elizabeth A, Beaumont, Jennifer L, Korytowsky, Beata, Bhattacharyya, Helen, Motzer, Robert
Publicado 2014

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma

por English, Patricia A, Williams, J Andrew, Martini, Jean-François, Motzer, Robert J, Valota, Olga, Buller, Richard E
Publicado 2016

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

por Blagoev, Krastan B., Wilkerson, Julia, Stein, Wilfred D., Motzer, Robert J., Bates, Susan E., Fojo, A. Tito
Publicado 2013

Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

por Stein, Andrew, Wang, Wenping, Carter, Alison A, Chiparus, Ovidiu, Hollaender, Norbert, Kim, Hyewon, Motzer, Robert J, Sarr, Celine
Publicado 2012

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

por Molina, Ana M., Hutson, Thomas E., Nosov, Dmitry, Tomczak, Piotr, Lipatov, Oleg, Sternberg, Cora N., Motzer, Robert, Eisen, Tim
Publicado 2018

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

por Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
Publicado 2013

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

por Motzer, Robert, George, Saby, Merchan, Jaime R, Hutson, Thomas E, Song, Xun, Perini, Rodolfo F, Xie, Ran, Bapat, Urmi, Puente, Javier
Publicado 2023

Sarcomatoid renal cell carcinoma: biology, natural history and management

por Blum, Kyle A., Gupta, Sounak, Tickoo, Satish K., Chan, Timothy A., Russo, Paul, Motzer, Robert J., Karam, Jose A., Hakimi, A. Ari
Publicado 2020

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

por DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Publicado 2007